Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 13, Issue 618, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abj2641
Keywords
-
Categories
Funding
- Bill & Melinda Gates Foundation [INV-027406, INV-006131]
- National Institutes of Health [CA260476, OD011106]
- Janssen Vaccines Prevention BV
- Musk Foundation, Massachusetts Consortium on Pathogen Readiness (MassCPR)
- Ragon Institute of MGH, MIT, and Harvard
- Bill and Melinda Gates Foundation [INV-006131, INV-027406] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Natural immunity induced by the original SARS-CoV-2 WA1/2020 strain provides partial but incomplete protection against the B.1.1.7 (alpha) and B.1.351 (beta) variants. Further research is needed to understand the implications for vaccination and public health strategies in the face of emerging SARS-CoV-2 variants of concern.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that result in increased transmissibility and partial evasion of neutralizing antibodies have recently emerged. Whether natural immunity induced by the original SARS-CoV-2 WA1/2020 strain protects against rechallenge with these SARS-CoV-2 variants remains a critical unresolved question. In this study, we show that natural immunity induced by the WA1/2020 strain leads to partial but incomplete protection against the SARS-CoV-2 variants B.1.1.7 (alpha) and B.1.351 (beta) in rhesus macaques. We challenged rhesus macaques with B.1.1.7 and B.1.351 and showed that infection with these variants resulted in high viral replication in the upper and lower respiratory tract. We then infected rhesus macaques with the WA1/2020 strain and rechallenged them on day 35 with the WA1/2020, B.1.1.7, or B.1.351 variants. Natural immunity to WA1/2020 led to robust protection against rechallenge with WA1/2020 but only partial protection against rechallenge with B.1.351. An intermediate degree of protection was observed in rhesus macaques against rechallenge with B.1.1.7. These data demonstrate partial but incomplete protective efficacy of natural immunity induced by WA1/2020 against SARS-CoV-2 variants of concern. Our findings have important implications for both vaccination and public health strategies in the context of emerging SARS-CoV-2 variants of concern.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available